Tavazzi L et al. Effect of Rosuvostatin In Patients With Chronic Heart-Failure. (The GISSI-HF Trial) a randomised, double-blind, placebo-controlled trial. Published in the Lancet 2008 Oct 4;372(9645):1231-9
The study (Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’Infarto Miocardico-Heart Failure: Rosuvastatin GISSI-HF) investigated the effects of rosuvastatin in patients with heart-failure.
The study was held at the University of Pavia and was headed-up by Dr Luigi Tavazzi, Professor of Cardiology. 4,574 patients aged 18 and older, with chronic heart-failure were assigned either rosuvastatin of 10mg daily (2,285) or a placebo (2,289) and were followed-up for 3.9 years. Statin doses post heart events are usually between 4 and 8 times this amount.
The trial showed that:
Statin users had a 4% increased risk of death from any reasons compared with the placebo.
Statin users had a 12% increased risk of sudden cardiac death compared with the placebo.
Statin users had a 23% increased risk of fatal & non-fatal stroke compared with the placebo.
Links to the supporting article can be found here: